Lensar unveils ALLY software upgrades

LENSAR used the ASCRS Annual Meeting to roll out software upgrades for its ALLY Adaptive Cataract Treatment System and to push new surgeon training around the platform, according to the company’s first-quarter 2026 earnings call transcript published June 1. Chief Executive Officer Nicholas Curtis told investors the company also used the meeting to increase demonstrations and distributor outreach as it tries to restart placements after a slower period tied to acquisition uncertainty. The update came as Lensar reported seven ALLY placements in the quarter, bringing the installed base to about 205 systems, with 11 more in backlog. ### What exactly did Lensar say it launched at ASCRS? Nicholas Curtis said on the May 8 earnings call that Lensar had “renewed focus on ALLY enhancements” and would share more details at industry meetings, while the upstream briefing tied that launch activity specifically to software upgrades and surgeon training introduced during the ASCRS meeting. The company’s public product materials describe ALLY as a robotic cataract laser platform built around imaging, treatment planning and workflow integration. (fool.com) LENSAR’s own product pages say the ALLY system uses “Adaptive Intelligence” to optimize femtosecond laser and phacoemulsification treatments, with cataract density imaging used to set fragmentation patterns and energy according to surgeon preferences. The same materials describe workflow features such as wireless transfer of pre-op diagnostic data, iris registration, astigmatism planning and a compact footprint designed for operating rooms or in-office surgical suites. (fool.com) ### Which software functions appear to be at the center of the update? LENSAR’s marketing and technology pages point to three areas that match the company’s description of the upgrade cycle: machine settings, fluidics-related efficiency, and workflow. The company says ALLY can customize fragmentation patterns based on cataract density, adapt energy settings to surgeon preferences, and support a sterile femto-to-phaco workflow intended to reduce overall energy delivered in the eye. (lls.lensar.com) The company also says the platform can save up to 17 minutes per case versus other laser cataract systems and reported up to a 27% reduction in mean phaco time compared with manual cataract surgery in cited materials on its site. Those figures come from company-posted references and are part of Lensar’s sales pitch for efficiency and workflow optimization rather than new ASCRS outcome data disclosed in the earnings transcript. (lls.lensar.com) ### How hard is Lensar pushing adoption? Curtis said Lensar conducted more than 50 system demonstrations at the ASCRS Annual Meeting, which he said confirmed surgeon and distributor interest. The same earnings transcript said the company received purchase orders from international distributors after the quarter ended, signaling a planned resumption of shipments outside the United States after about a year of inactivity. (lensar.com) First-quarter results show why the company is emphasizing adoption. Lensar reported total revenue of $13.4 million, down 5% from a year earlier, with system revenue falling to $800,000 from $2.6 million, while recurring revenue rose 9% to $12.6 million and made up 94% of total revenue. U.S. procedure market share was 23.4% at quarter end, unchanged from Dec. 31, the transcript said. (fool.com) ### Where does surgeon training fit into the rollout? LENSAR operates a customer clinical training portal and says on its support pages that it offers a “full spectrum of support” to help practices optimize use of its technology. That makes the ASCRS training push part of a broader effort to pair software and platform updates with onboarding and utilization support for surgeons already using ALLY or considering it. (fool.com) Company materials linked to ASCRS also highlighted papers on astigmatism management, capsulotomy precision and intraocular lens positioning with the ALLY system. Those materials suggest Lensar used the meeting not only for product marketing but also to reinforce the clinical case for the platform with surgeons attending the conference. ### What comes next from here? (clinicaltraining.lensar.com) Curtis told investors on May 8 that Lensar would provide further details on additional corneal procedure enhancements and increased robotic features at upcoming industry meetings. The next public markers for the rollout are likely to be those meeting presentations and any follow-up disclosures tied to the 11 systems Lensar said were in backlog at the end of the first quarter. (fool.com) (get.lensar.com)